Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(1.62)
# 3,106
Out of 4,829 analysts
54
Total ratings
22.92%
Success rate
-8.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $5.08 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $20.02 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $1.26 | - | 1 | Mar 18, 2025 | |
| MTSR Metsera | Initiates: Overweight | n/a | $23.87 | - | 1 | Feb 25, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $13.65 | - | 3 | Jan 21, 2025 | |
| ATYR aTyr Pharma | Initiates: Overweight | n/a | $3.28 | - | 1 | Jan 6, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Overweight | $10 | $5.02 | +99.20% | 1 | Dec 17, 2024 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $299.69 | - | 4 | Nov 20, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $25.57 | +154.20% | 12 | Sep 23, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $38.39 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $39.85 | - | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.75 | - | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $33.64 | -28.66% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.81 | +15,914.23% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $0.39 | +3,485.15% | 1 | Mar 3, 2021 |
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.08
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.02
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.26
Upside: -
Metsera
Feb 25, 2025
Initiates: Overweight
Price Target: n/a
Current: $23.87
Upside: -
Keros Therapeutics
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $13.65
Upside: -
aTyr Pharma
Jan 6, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.28
Upside: -
TriSalus Life Sciences
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $5.02
Upside: +99.20%
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $299.69
Upside: -
Structure Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $65
Current: $25.57
Upside: +154.20%
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.39
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $39.85
Upside: -
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.75
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $33.64
Upside: -28.66%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.81
Upside: +15,914.23%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.39
Upside: +3,485.15%